Literature DB >> 16641930

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

S Moe1, T Drüeke, J Cunningham, W Goodman, K Martin, K Olgaard, S Ott, S Sprague, N Lameire, G Eknoyan.   

Abstract

Disturbances in mineral and bone metabolism are prevalent in chronic kidney disease (CKD) and are an important cause of morbidity, decreased quality of life, and extraskeletal calcification that have been associated with increased cardiovascular mortality. These disturbances have traditionally been termed renal osteodystrophy and classified based on bone biopsy. Kidney Disease: Improving Global Outcomes (KDIGO) sponsored a Controversies Conference on Renal Osteodystrophy to (1) develop a clear, clinically relevant, and internationally acceptable definition and classification system, (2) develop a consensus for bone biopsy evaluation and classification, and (3) evaluate laboratory and imaging markers for the clinical assessment of patients with CKD. It is recommended that (1) the term renal osteodystrophy be used exclusively to define alterations in bone morphology associated with CKD, which can be further assessed by histomorphometry, and the results reported based on a unified classification system that includes parameters of turnover, mineralization, and volume, and (2) the term CKD-Mineral and Bone Disorder (CKD-MBD) be used to describe a broader clinical syndrome that develops as a systemic disorder of mineral and bone metabolism due to CKD, which is manifested by abnormalities in bone and mineral metabolism and/or extra-skeletal calcification. The international adoption of these recommendations will greatly enhance communication, facilitate clinical decision-making, and promote the evolution of evidence-based clinical practice guidelines worldwide.

Entities:  

Mesh:

Year:  2006        PMID: 16641930     DOI: 10.1038/sj.ki.5000414

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  555 in total

1.  Vitamin D status of children receiving chronic dialysis.

Authors:  Basema I Dibas; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2012-06-03       Impact factor: 3.714

2.  The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.

Authors:  Dan Li; Leping Shao; Haiyan Zhou; Wei Jiang; Wei Zhang; Yan Xu
Journal:  Endocrine       Date:  2012-06-06       Impact factor: 3.633

3.  Soy protein diet and exercise training increase relative bone volume and enhance bone microarchitecture in a mouse model of uremia.

Authors:  Emily J Tomayko; Hae R Chung; Kenneth R Wilund
Journal:  J Bone Miner Metab       Date:  2011-06-03       Impact factor: 2.626

Review 4.  Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Chun-Juan Zhai; Xiao-Wei Yang; Jing Sun; Rong Wang
Journal:  Int Urol Nephrol       Date:  2014-11-16       Impact factor: 2.370

Review 5.  Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis.

Authors:  M Fusaro; A D'Angelo; G Scalzo; M Gallieni; S Giannini; G Guglielmi
Journal:  J Endocrinol Invest       Date:  2010-05       Impact factor: 4.256

6.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

7.  Heart Failure Associated with Metastatic Myocardial Calcification in a Hemodialysis Patient with Progressive Calcification of the Hand.

Authors:  Masaru Matsui; Satoshi Okayama; Akihiro Takitsume; Katsuhiko Morimoto; Kenichi Samejima; Shiro Uemura; Yoshihiko Saito
Journal:  Cardiorenal Med       Date:  2012-10-24       Impact factor: 2.041

8.  Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.

Authors:  Matthew R Allen; Neal X Chen; Vincent H Gattone; Sharon M Moe
Journal:  Am J Nephrol       Date:  2013-11-22       Impact factor: 3.754

9.  Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

Authors:  Toshifumi Sugatani; Olga A Agapova; Yifu Fang; Alycia G Berman; Joseph M Wallace; Hartmut H Malluche; Marie-Claude Faugere; William Smith; Victoria Sung; Keith A Hruska
Journal:  Kidney Int       Date:  2016-09-22       Impact factor: 10.612

Review 10.  Expansive renal osteitis fibrosa: a case report.

Authors:  Gabriel Silva Andrade; Abrahão Cavalcante Gomes de Souza Carvalho; Tibério Gomes Magalhães; Edson Luiz Cetira Filho; Roberta Barroso Cavalcante; Renato Luiz Maia Nogueira
Journal:  Oral Maxillofac Surg       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.